Affiliation:
1. Department of Endocrinology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia
Abstract
Aim: To evaluate a possible role of CYP2C9 genotyping for sulfonylureas (SUs) prescription in Russia. Materials & methods: We have collected the current data on correlation between SUs pharmacodynamics and CYP2C9 polymorphisms. We have evaluated the frequency of CYP2C9 polymorphisms in Russia by reviewing the literature published from 2004 to 2015 on Russian CYP2C9. Results: The genotype *1/*1, which confers risk for treatment failure, has a higher frequency (81.92%) in the non-Caucasians than that (64.92%) in the Caucasians. The Caucasians have a frequency (3.58%) of the poor metabolizers (*2/*2, *2/*3 and *3/*3) eight-times higher than that (0.44%) in the non-Caucasians, predisposing an increased risk of hypoglycemia. Conclusion: Considering the received data and the existed knowledge on CYP2C9 influence on SUs pharmacokinetics and pharmacodynamics, we propose a possible approach to CYP2C9-guided SUs prescription for Russians.
Subject
Pharmacology,Genetics,Molecular Medicine
Reference52 articles.
1. World Health Organization. Global Health Estimates: deaths by cause, age, sex and country, 2000–2012. WHO, Geneva, Switzerland (2014).
2. World Health Organization. Projections of mortality and causes of death, 2015 and 2030. www.who.int/healthinfo/global_burden_disease/projections/en/.
3. Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS)
4. Multifaceted Determinants for Achieving Glycemic Control
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献